Could Arbutus Biopharma Corporation (NASDAQ:ABUS) Skyrocket? The Stock Had Too Little Sellers

Arbutus Biopharma Corporation (NASDAQ:ABUS) Logo

The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) registered a decrease of 3.39% in short interest. ABUS’s total short interest was 929,200 shares in July as published by FINRA. Its down 3.39% from 961,800 shares, reported previously. With 98,700 shares average volume, it will take short sellers 9 days to cover their ABUS’s short positions. The short interest to Arbutus Biopharma Corporation’s float is 3%.

The stock increased 2.13% or $0.05 during the last trading session, reaching $2.4. About 241,581 shares traded. Arbutus Biopharma Corporation (NASDAQ:ABUS) has declined 64.21% since July 14, 2018 and is downtrending. It has underperformed by 68.64% the S&P500.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $140.43 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

More notable recent Arbutus Biopharma Corporation (NASDAQ:ABUS) news were published by: which released: “The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut – Benzinga” on May 23, 2019, also with their article: “Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release – Nasdaq” published on April 25, 2019, published: “Microcaps mostly among midday movers – Seeking Alpha” on June 20, 2019. More interesting news about Arbutus Biopharma Corporation (NASDAQ:ABUS) were released by: and their article: “3 Biotech Stocks That Soared This Week: Are They Buys? – Yahoo Finance” published on July 07, 2018 as well as‘s news article titled: “Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS) – Yahoo Finance” with publication date: July 04, 2019.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.